Literature DB >> 11114631

Is calciphylaxis best treated surgically or medically?

A S Kang1, J T McCarthy, C Rowland, D R Farley, J A van Heerden.   

Abstract

BACKGROUND: Calciphylaxis is a rare, painful, life-threatening problem of cutaneous necrosis and refractory healing in patients with uremia and secondary hyperparathyroidism. The pathogenesis involves abnormalities in calcium and phosphorus metabolism and acute deposition of calcium in tissues.
METHOD: The clinical course of 16 patients who were diagnosed with calciphylaxis at our institution from 1994 through 1998 was reviewed.
RESULTS: Fourteen female patients and 2 male patients had chronic renal disease, secondary hyperparathyroidism, and characteristic skin necrosis (mean age, 56 years; range, 39-70 years). All patients underwent intensive medical therapy, including ongoing hemodialysis (n = 16 patients), parathyroidectomy (n = 7 patients), and debridement of cutaneous lesions (n = 8 patients). Mean serum values in surgical and nonsurgical patients were significantly different for phosphorus, calcium-phosphorus product, and parathormone levels. Median survival was 9.4 months; 15 patients (93%) have died. The median survival time for parathyroidectomy versus nonparathyroidectomy was 14.8 and 6.3 months (P =.22), for skin debridement versus nondebridement was 14.1 and 6.1 months (P =.08), and for diabetic versus nondiabetic patients was 6.5 and 13.9 months (P =.11).
CONCLUSIONS: Calciphylaxis has a female preponderance, with a dismal prognosis. A multidisciplinary approach that uses frequent hemodialysis to normalize calcium and phosphorus levels and local debridement of skin lesions seems prudent. Parathyroidectomy cannot be recommended routinely in all patients, unless severe hyperparathyroidism mandates intervention.

Entities:  

Mesh:

Year:  2000        PMID: 11114631     DOI: 10.1067/msy.2000.110429

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

1.  [Painful ulcerating livid erythema in a 58-year old patient].

Authors:  D Hoeft; U Hillen; M Goos; J Dissemond
Journal:  Hautarzt       Date:  2004-06       Impact factor: 0.751

2.  Secondary hyperparathyroidism: Uncommon cause of a leg ulcer.

Authors:  L B van Rijssen; E E A Brenninkmeijer; E J M Nieveen van Dijkum
Journal:  Int J Surg Case Rep       Date:  2011-10-28

Review 3.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

4.  Photoletter to the editor - Calciphylaxis: a diagnostic and therapeutic challenge.

Authors:  Hugo Marques Barreiros; João Goulão; Henriqueta Cunha; Elvira Bártolo
Journal:  J Dermatol Case Rep       Date:  2013-06-30

5.  Painful skin ulcers in a hemodialysis patient.

Authors:  Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

6.  Breast necrosis: calciphylaxis a rare cause.

Authors:  Joseph J Thornton; James Dolph
Journal:  Can J Plast Surg       Date:  2008

7.  [Calciphylaxis. A less well-known, clinically relevant disease].

Authors:  J D Strehl; V Brandenburg; C Forster; C Willam; A Hartmann; K Amann
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

8.  Cutaneous abnormalities in patients with end stage renal failure on chronic hemodialysis. A study of 458 patients.

Authors:  Abderrahmen Masmoudi; Mounira Hajjaji Darouiche; Haifa Ben Salah; Mohamed Ben Hmida; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2014-12-31

Review 9.  The surgical management of renal hyperparathyroidism.

Authors:  Catherine Madorin; Randall P Owen; William D Fraser; Phillip K Pellitteri; Brian Radbill; Alessandra Rinaldo; Raja R Seethala; Ashok R Shaha; Carl E Silver; Matthew Y Suh; Barrie Weinstein; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-20       Impact factor: 2.503

10.  Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment.

Authors:  E K Spanakis; D E Sellmeyer
Journal:  Osteoporos Int       Date:  2013-11-29       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.